CClinicalTrials.gg
RecruitingNCT04423484GFANEPHRO20Updated Mar 2, 2026

Therapeutic Recommendations for Nephroblastoma

An observational study in Nephroblastoma, sponsored by French Africa Pediatric Oncology Group. Recruiting at 7 sites in 6 countries. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by French Africa Pediatric Oncology Group · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
6 Months to 18 Years
Sex
All
01

Study summary

The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.

Read the detailed description

The study is based on results form 2 previous studies carried out by the GFAOP. This study aims to evaluate the capacity of units to follow the recommendations in the protocol. It will look mainly at treatment compliance and outcome for the children treated. The study will also evaluate the improvement in treatment compliance and reporting. This work will help the group to evaluate future needs in participating units and help us adapt treatment programmes to local conditions.

02

Conditions studied

  • Nephroblastoma

Browse trials for

03

Who can participate

Ages eligible
6 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All children with local Nephroblastoma in all participating units

Inclusion criteria

Unilateral Nephroblastoma Tumor Not previously treated The general health of the child will permit treatment.

Exclusion criteria

.

Exclusion Criteria:

Bilateral Nephroblastoma tumor Previously treated Disease too advanced Doubt concerning the diagnosis Treatment Refusal

04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Children with Nephroblastoma

    All children coming into the participating units with suspected Nephroblastoma.

    Other: Data collection

Interventions

  • OtherData collection

    Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.

05

What researchers measure

Primary outcomes

  1. Evaluation of the number of cases with local disease.

    By evaluating the initial clinical reports and later histological reports to confirm the stage and the diagnosis.

    Time frame: 5 years

  2. Evaluation of the number of cases with stage IV disease.

    By evaluating the initial clinical reports and later histological reports to confirm the stage.

    Time frame: 5 Years

  3. Evaluating the treatment given.

    Comparison of treatment given and recommended treatment.

    Time frame: 5 Years

  4. Evaluating the follow up after treatment.

    How many children alive or dead after treatment

    Time frame: 5 Years

Secondary outcomes

  1. Why has treatment failed

    look at precision of reporting by comparing reports (histological and surgical)

    Time frame: 5 years

06

Study locations

7 of 7 sites recruiting
  • Centre Hospitalier Universitaire Pédiatrique Charles De Gaulle
    Ouagadougou, Burkina Faso
    • Sonia Ms Kaboret, Dr · Contact
    • kawajo200046@gmail.com · Contact
    Recruiting
  • CHU de Treichville à ABIDJAN
    Abidjan, Abidjan Autonomous District, Côte d’Ivoire
    • Line Guei COUITCHERE, MD · Contact
    Recruiting
  • CUK (Cliniques Universitaires de Kinshasa)
    Kinshasa, BP 12 KIN XI, Democratic Republic of the Congo
    Recruiting
  • Cliniques Universitaires de Lubumbashi (CUL)
    Lubumbashi, BP 1825, Democratic Republic of the Congo
    Recruiting
  • HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona
    Antananarivo, Madagascar
    • Mbola Mr RAKOTOMAHEFA, Dr · Contact · mahefambola@yahoo.fr
    • Mbola RAKOTOMAHEFA, Dr · Principal investigator
    Recruiting
  • CHU Gabriel Touré (HGT)
    Bamako, Mali
    Recruiting
  • Hôpital Aristide Le Dantec, Avenue Pasteur, BP 3001
    Dakar, Dakar, Senegal
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04423484
Lead sponsor
French Africa Pediatric Oncology Group
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
Jul 1, 2020
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Mar 2, 2026

Study contacts

BRENDA Ms MALLON, MSC
Contact
brenda.mallon@gustaveroussy.fr
0033142115411
Fatou Binetou Ms DIAGNE AKONDE, Dr
principal investigator · French Africa Pediatric Oncology Group

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion